Title:
PAR-4 ANTAGONISTS FOR USE IN THE TREATMENT OR PREVENTION OF INFLUENZA VIRUS TYPE A INFECTIONS
Document Type and Number:
WIPO Patent Application WO/2014/173859
Kind Code:
A3
Abstract:
The present invention provides methods and compositions (such as pharmaceutical compositions) comprising PAR4 antagonists for treating or preventing influenza virus type A infections, in particular H1N1 infection. PAR4 antagonists may be combined with a PAR2 agonist or a PAR1 antagonist.
More Like This:
Inventors:
RITEAU BÉATRICE (FR)
L BA VUONG (FR)
LINA BRUNO (FR)
L BA VUONG (FR)
LINA BRUNO (FR)
Application Number:
PCT/EP2014/058052
Publication Date:
December 31, 2014
Filing Date:
April 22, 2014
Export Citation:
Assignee:
AGRONOMIQUE INST NAT RECH (FR)
HOSPICES CIVILS LYON (FR)
UNIV CLAUDE BERNARD LYON (FR)
HOSPICES CIVILS LYON (FR)
UNIV CLAUDE BERNARD LYON (FR)
International Classes:
A61K38/55
Domestic Patent References:
| WO2011058183A1 | 2011-05-19 |
Other References:
LAN R S ET AL: "Altered expression and in vivo lung function of protease-activated receptors during influenza virus A infection in mice", AMERICAN JOURNAL OF PHYSIOLOGY. LUNG CELLULAR AND MOLECULAR PHYSIOLOGY, AMERICAN PHYSIOLOGICAL SOCIETY, US, vol. 286, 1 February 2004 (2004-02-01), pages L388 - L398, XP002574093, ISSN: 1040-0605, [retrieved on 20031121], DOI: 10.1152/AJPLUNG.00286.2003
KHOUFACHE K ET AL: "Protective Role for Protease-Activated Receptor-2 against Influenza Virus pathogenesis via an IFN-gamma-Dependent Pathway", THE JOURNAL OF IMMUNOLOGY, THE AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, vol. 182, no. 12, 1 June 2009 (2009-06-01), pages 7795 - 7802, XP002574092, ISSN: 0022-1767, DOI: 10.4049/JIMMUNOL.0803743
VERGNOLLE ET AL: "Protease-activated receptors as drug targets in inflammation and pain", PHARMACOLOGY AND THERAPEUTICS, ELSEVIER, GB, vol. 123, no. 3, 1 September 2009 (2009-09-01), pages 292 - 309, XP026421540, ISSN: 0163-7258, [retrieved on 20090528]
PETERS TERENCE ET AL: "Protease-activated receptors and prostaglandins in inflammatory lung disease", BRITISH JOURNAL OF PHARMACOLOGY, vol. 158, no. 4, October 2009 (2009-10-01), pages 1017 - 1033, XP002698552, ISSN: 0007-1188, DOI: 10.1111/J.1476-5381.2009.00449.X
KHOUFACHE K ET AL: "Protective Role for Protease-Activated Receptor-2 against Influenza Virus pathogenesis via an IFN-gamma-Dependent Pathway", THE JOURNAL OF IMMUNOLOGY, THE AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, vol. 182, no. 12, 1 June 2009 (2009-06-01), pages 7795 - 7802, XP002574092, ISSN: 0022-1767, DOI: 10.4049/JIMMUNOL.0803743
VERGNOLLE ET AL: "Protease-activated receptors as drug targets in inflammation and pain", PHARMACOLOGY AND THERAPEUTICS, ELSEVIER, GB, vol. 123, no. 3, 1 September 2009 (2009-09-01), pages 292 - 309, XP026421540, ISSN: 0163-7258, [retrieved on 20090528]
PETERS TERENCE ET AL: "Protease-activated receptors and prostaglandins in inflammatory lung disease", BRITISH JOURNAL OF PHARMACOLOGY, vol. 158, no. 4, October 2009 (2009-10-01), pages 1017 - 1033, XP002698552, ISSN: 0007-1188, DOI: 10.1111/J.1476-5381.2009.00449.X
Attorney, Agent or Firm:
CABINET PLASSERAUD / GROUPEMENT 280 (Paris Cedex 09, FR)
Download PDF: